Community Mental Health & SUD Treatment Services

The analytical move SD3 establishes is that the gap between Olmstead-mandated community services plus EPSDT entitlement plus SUPPORT Act IMD parity and operational capacity is the central representation gap in D3, and the SUD-MH treatment integration challenge compounds it. SD3 is the federal-rep-leverage-richest sub-domain in D3: MHBG and SABG appropriations, Medicaid rate-setting, CCBHC expansion (CCBHC stream protected by OBBBA exemption from new cost-sharing), HRSA NHSC, IMD exclusion modification (NACo H.R. 5462 / H.R. 6727 pending; IMD framework unchanged by OBBBA), SAMHSA capacity restoration, and OBBBA implementation specifics (state-directed payment caps plus provider tax phase-down FY28-34). Operationally: approximately 2,000-3,000 PA-3 residents with SMI eligible for ACT (Assertive Community Treatment) but unserved due to capacity constraints; 4-8 week wait times for adult outpatient mental health and 3-6 months for child / adolescent specialty; the phantom-provider network adequacy problem (CBH formally meets the 200+ contracted-provider standard but operational capacity is reduced by providers in network not accepting new patients, accepting only at reduced capacity, or maintaining nominal participation); HPSA-MH designations cluster in the same PA-3 sub-areas documented as redlined-mapped and Black-population-concentrated; the X-waiver elimination (CAA 2023 § 1262 of Division FF, effective December 29, 2022) removed prior restriction on buprenorphine prescribing without producing proportionate workforce expansion; methadone OTPs concentrated in specific geographic locations create daily-dosing burden; co-occurring SMI plus SUD population (approximately 7,000-10,000 dual-diagnosis adults in PA-3) faces the OMHSAS-DDAP state-level bifurcation reconciled at local level by DBHIDS SCA-MH consolidation but with operational dual-diagnosis treatment integration variable.

Legal Architecture

Constitutional foundation

ADA Title II plus Section 504 plus the Olmstead integration mandate (Olmstead v. L.C., 527 U.S. 581 (1999)) ground the federal community-services obligation: states must provide community-based services in the most integrated setting appropriate when treatment professionals so determine, the affected person does not oppose, and reasonable accommodation is possible given resources. The Olmstead Plan operationalizes this at state level. 14th Amendment Due Process operates narrowly through Youngberg (treatment standards in committed settings — operative when § 304(f) outpatient commitment is invoked). PA Const. Art. I § 1 (inherent rights) provides PA-specific procedural floor; the state's parens patriae and police-power authorities ground community-services administrative architecture.

Federal statutory layer

Public Health Service Act Title XIX-B Mental Health Block Grant, 42 U.S.C. § 300x-1 et seq., and Substance Abuse Block Grant, 42 U.S.C. § 300x-21 et seq. MHBG funds community MH for adults with SMI plus children with SED; SABG funds SUD treatment plus prevention. PA OMHSAS receives MHBG; PA DDAP receives SABG; both pass through to DBHIDS (consolidated at city level). Statutory stability: STABLE.

Medicaid behavioral health entitlement, 42 U.S.C. § 1396 et seq.; HealthChoices state plan. Medicaid covers community MH plus SUD services as state plan plus EPSDT (children) plus § 1115 waivers (including SUD IMD waiver). Operative through HealthChoices BH (CBH MCO) for Philadelphia. Statutory stability: STABLE; rate-setting administrative.

21st Century Cures Act § 223 (CCBHC), P.L. 114-255. Federally-certified community BH provider model with nine required service components funded via Medicaid PPS (cost-based per-visit); PA participates with multiple Philadelphia certifications. The Bipartisan Safer Communities Act of 2022 (P.L. 117-159) expanded CCBHC. The separate BSCA $1 billion school-MH grant stream was targeted for termination April 29, 2025 (treated in the Children's Behavioral Health sub-domain); the CCBHC component of BSCA is distinct from the school-MH stream. Statutory stability: GROWING. OBBBA exempted CCBHCs (plus FQHCs and RHCs) from new $1-$35 cost-sharing — the protective provision for the D3-relevant CCBHC stream.

Olmstead enforcement framework via ADA Title II plus Section 504 plus DOJ CRD plus HHS OCR enforcement. Stability: STABLE textually; enforcement variable.

SUPPORT Act IMD parity for SUD, P.L. 115-271 § 1012; 42 U.S.C. § 1396n(l). Partial Medicaid IMD-exclusion erosion for SUD treatment in facilities up to 16 beds; 1115 IMD waivers extend further. IMD exclusion at 42 U.S.C. § 1396d(a)(B) unchanged by OBBBA per TC-03; the SUPPORT Act IMD parity for SUD framework is also unchanged. NACo-led legislative reform (H.R. 5462 plus H.R. 6727 pending) is the active federal-rep lever on IMD, not OBBBA.

Methadone OTP framework, 42 C.F.R. Part 8. DEA plus SAMHSA jointly regulate OTP operations; PA OTPs concentrated in specific geographic locations. Stability: STABLE.

Consolidated Appropriations Act 2023 X-waiver elimination, P.L. 117-328 § 1262 of Division FF. Effective immediately upon enactment December 29, 2022. Any DEA-registered practitioner can prescribe buprenorphine without prior special waiver. Implementation gap: legal change has not produced proportionate workforce expansion; supply-side shortage persists.

ACA EHB MH/SUD inclusion, 42 U.S.C. § 18022(b)(1)(E). Mandatory inclusion in qualified health plans plus individual market plus Medicaid expansion population. Stability: STABLE post-Braidwood (cross-reference D2 Public Health for Braidwood resolution detail).

EPSDT, 42 U.S.C. § 1396d(r). Medicaid entitlement for children under 21 to all medically necessary services; covers community MH services for SED children plus SUD treatment for adolescents. Stability: STABLE.

HRSA HPSA-MH designation framework plus NHSC loan repayment. Operative for community MH workforce capacity in HPSA-designated areas including PA-3 sub-areas.

FQHC § 330 integrated BH, 42 U.S.C. § 254b. Per the verified D2 file: Community Health Center Fund mandatory funding extended only through December 2026; OBBBA Medicaid cuts threaten the multi-year horizon.

Federal regulatory layer

42 C.F.R. Part 438 (Medicaid managed care) — CCBHC PPS rules; network adequacy floors at § 438.68; parity for Medicaid MCOs. 42 C.F.R. Part 8 (OTP regulation) — licensure, clinical operations, Schedule II prescribing requirements. 42 C.F.R. Part 96 (block grant administrative provisions for MHBG plus SABG). 42 C.F.R. § 438.68 (network adequacy specifically). 45 C.F.R. Parts 92 and 93 (HHS Section 504 / ADA implementation including Olmstead in HHS-funded programs).

Federal agency layer

SAMHSA. MHBG plus SABG administration; CCBHC certification plus grants; State Opioid Response discretionary grants. Vulnerability: HIGH. Comprehensive capacity erosion verified per TC-06 (AHA reorganization March 27, 2025; >50% staff reduction; January 14-15, 2026 grant-termination/reversal episode). Treated in detail in the Infrastructure sub-domain.

CMS. Medicaid MCO oversight (CBH parity plus network adequacy); CCBHC PPS rule administration; IMD-exclusion guidance; 1115 SUD IMD waiver approvals. Vulnerability: MODERATE-HIGH. OBBBA implementation phases FY28-34; CCBHC stream protected by exemption from new cost-sharing; IMD framework unchanged.

HRSA. HPSA-MH designations; NHSC loan repayment; FQHC § 330 plus integrated BH; THCGME residency. Vulnerability: MODERATE.

DEA. OTP registration plus Schedule II oversight; X-waiver elimination administrative implementation. Vulnerability: MODERATE. DEA Schedule III rescheduling for state-licensed medical cannabis (April 22-28, 2026) cross-references D2 Public Health SD7.

HHS OCR plus DOJ CRD. Olmstead enforcement co-authority. Vulnerability: MODERATE-HIGH under the current administration.

State statutory layer

PA Code Title 55 Chapter 5230 — PROS (Psychiatric Rehabilitation and Recovery Services). Medicaid-covered psychiatric rehabilitation; skills training plus community integration. Stability: STABLE.

PA Code Title 55 plus Title 50 — community MH service standards generally; ACT team certification standards.

PA Drug and Alcohol Service System Act, 71 P.S. § 1690.101 et seq. Counties as SCAs; DDAP as state authority; DBHIDS uniquely combines SCA plus county MH authority.

PA Act 30 of 2020 — BH-physical health Medicaid integration mandate. Implementation status partially unverified.

PA Medicaid HealthChoices Behavioral Health delivery system. Multi-MCO PH; single-MCO BH in Philadelphia (CBH).

PA PROS coverage breadth and DBHIDS SCA-MH consolidation are PA-state framework distinctive features beyond the federal floor.

Local layer — DBHIDS contract network

DBHIDS contract network architecture. State-designated county MH authority plus SCA for SUD; contract network of 200+ providers. Major BH providers: Horizon House; Resources for Human Development; NHS Human Services (closed/consolidated 2018-2019; partial reorganization); JEVS Human Services; Public Health Management Corporation (PHMC); Salvation Army Behavioral Health; Bridge Way (Tower Health affiliate). Specialty SUD providers: Gaudenzia (largest PA SUD residential network); Self Help Movement; NorthEast Treatment Centers; Eagleville Hospital (just outside Philadelphia). Methadone OTPs: NET Lehigh and others; geographic distribution concentrated in specific tracts. FQHC integrated BH: PHMC; Esperanza Health Center (adjacent); Drexel 11th Street Family Health; Philadelphia FIGHT (integrating BH with HIV care); Spectrum Health Services. ACT teams: 15-20 across providers; capacity approximately $15,000-25,000 per person annually; waitlists 2,000-3,000 unserved estimate.

PROS sites plus outpatient MH program network. Approximately 50-60 outpatient MH programs in DBHIDS network; PROS sites; partial hospitalization plus intensive outpatient programs; recovery community centers (approximately 300-400 certified peer specialists).

CRC plus CMCRT/CIRT plus crisis residential. Treated in the Crisis Infrastructure sub-domain.

Home Rule authority. DBHIDS direct federal-grant relationships (MHBG, SABG, SAMHSA discretionary, HRSA grants); CBH nonprofit-MCO authority; CMCRT plus CIRT interagency authority; CASSP coordination authority. Limits: cannot supersede PA OMHSAS clinical standards; cannot relax MHPAEA; subject to OMHSAS plus CMS oversight.

Cross-cutting structural features

Feature 1 — ACT team waitlist as Olmstead-mandate operational shortfall. Approximately 2,000-3,000 PA-3 residents with SMI eligible for ACT but unserved due to capacity constraints. ACT is the highest-intensity community-based service for SMI; the waitlist directly contradicts the Olmstead community-integration mandate.

Feature 2 — Outpatient MH wait time as network-adequacy operational failure. 4-8 week adult wait time plus 3-6 month child/adolescent specialty wait time exceeds reasonable network-adequacy benchmarks. CBH is formally compliant; operationally degraded.

Feature 3 — X-waiver elimination implementation gap. CAA 2023 X-waiver elimination removed the prior restriction on buprenorphine prescribing; the legal change has not produced proportionate workforce expansion. Supply-side shortage persists because rate inadequacy, training, and cultural factors all separately constrain prescribing growth.

Feature 4 — Bifurcated SUD-MH treatment integration challenge. Co-occurring SMI plus SUD population (approximately 7,000-10,000 dual-diagnosis adults in PA-3) faces the OMHSAS-DDAP state-level bifurcation reconciled at the local level by DBHIDS SCA-MH consolidation. Operational dual-diagnosis treatment integration variable; patients fall through coordination gaps. The CCBHC nine-component model is designed to address this; the September 2024 MHPAEA Final Rule (non-enforcement statement May 15, 2025) plus PA Act 30 of 2020 implementation are the policy levers.

Feature 5 — OTP geographic distribution plus daily-dosing burden. Methadone OTPs concentrated in specific Philadelphia geographic locations (Kensington-adjacent for SUD-treatment historical reasons); daily dosing requirement burdens PA-3 residents with transportation plus work-schedule conflicts; PA-3 residents may travel to non-PA-3 OTPs (Kensington area outside PA-3 strict boundary; NET Lehigh in Northeast Philadelphia).

Feature 6 — HPSA-MH provider shortage compounds with cumulative-disadvantage geography. HPSA-MH designations cluster in the same PA-3 sub-areas (North/Northwest Core; parts West; parts Northwest) documented as redlined-mapped (HOLC 1937) and Black-population-concentrated. The provider-density geography reproduces the cumulative-disadvantage pattern documented across the verified D2 file. Workforce-cultural-competency gap and voluntary-utilization underutilization compound the geography.

Constituent profiles

These profiles illustrate the structural features above. The pathways are drawn from current law applied to documented PA-3 conditions; the people are composites with no claim to identifiable individuals.

Profile 1: Medicaid-enrolled adult with SMI seeking outpatient MH

Constituent type: a PA-3 adult enrolled in HealthChoices Medicaid (covered by CBH; one of approximately 220,000-260,000 PA-3 Medicaid beneficiaries) experiencing SMI symptoms — major depression with psychotic features, bipolar disorder, schizophrenia spectrum, or severe PTSD — seeking outpatient mental health care.

Pathway through the institutional system. Call CBH Member Services. Routed to one of approximately 50-60 in-network outpatient programs; appointment 4-8 weeks out. Initial appointment: medication management plus therapy referral. Ongoing care faces the phantom-provider problem (provider full; new patient closed); the session-cap NQTL of 8-10 sessions vs. medical/surgical no-cap; rate-driven workforce turnover. ACT team referral if SMI plus high-utilization indicators: waitlist 6+ months across providers (approximately 2,000-3,000 unserved citywide). PROS access for psychiatric rehabilitation if appropriate.

Outcome. Step 2 wait time pushes some constituents to crisis pathway by attrition. Step 4 phantom-provider plus cultural-mismatch produces continuity-of-care erosion. The Olmstead-mandated community-services architecture exists; its operational expression falls below the mandate's intent.

Profile 2: Medicaid-enrolled adult with OUD seeking MAT

Constituent type: a PA-3 adult enrolled in HealthChoices Medicaid with opioid use disorder (one of approximately 15,000-25,000 PA-3 residents with OUD per structural inference from the verified D2 file) seeking medication-assisted treatment.

Pathway through the institutional system. First-level decision: MAT through OTP (methadone) vs. OBOT (buprenorphine in primary care plus BH). OTP route: limited geographic locations; daily dosing requirement burdens transportation plus work; PA-3 residents may travel to Kensington-area providers (outside PA-3 strict boundary) or NET Lehigh in Northeast Philadelphia. OBOT route: any DEA-registered prescriber post-X-waiver elimination; supply remains limited; FQHC integrated BH (PHMC, Spectrum, FIGHT, Drexel 11th Street) provides some access; private PCPs uncommon in Medicaid. Co-occurring SMI: DBHIDS-CBH integration through SCA-MH consolidation theoretically supports dual-diagnosis treatment; operational integration variable.

Outcome. OTP geographic plus daily-dosing burden. OBOT supply-side gap despite legal reform. Dual-diagnosis coordination operational gaps. The substantive X-waiver elimination has not translated to proportionate workforce expansion at three years post-enactment; Medicaid rate inadequacy, training-pipeline limitations, and cultural-mismatch each separately constrain prescribing growth.

Profile 3: Uninsured PA-3 adult with SMI or SUD

Constituent type: a PA-3 adult uninsured (one of approximately 60,000-90,000 PA-3 uninsured residents) with SMI or SUD seeking community services.

Pathway through the institutional system. FQHC integrated BH (PHMC, Spectrum, FIGHT, Drexel 11th Street) sliding-fee scale; capacity-constrained; Medicaid-billable services preferred which structurally limits uninsured access. DBHIDS direct-funded base services through the county-base-service stream — chronically capacity-constrained. Crisis-only access via CRC plus ED plus EMTALA — no continuity guarantee.

Outcome. FQHC plus base-service capacity strained at every step. Episodic-care-without-continuity pattern. Insurance-eligibility cycling produces churn — emergency Medicaid activates for inpatient crisis episodes, then is lost post-discharge. The "Pathway B" side of the SD1 bifurcation operating with particular acuity at the SUD continuum where ASAM-level capacity (residential, MAT-integrated outpatient) is constrained by rate inadequacy plus workforce gaps.

Conversational note

SD3 is the central representation gap in D3. The legal architecture — Olmstead community-integration mandate, EPSDT entitlement, ACA EHB inclusion, CCBHC framework, SUPPORT Act IMD parity for SUD, MHBG and SABG block grants, HRSA HPSA-MH designation framework — is comprehensive. The operational capacity systematically falls below what the legal mandates require. The 2,000-3,000 ACT team waitlist is the most operationally specific shortfall against Olmstead. The 4-8 week adult outpatient and 3-6 month child/adolescent specialty wait times are the most operationally specific shortfall against network-adequacy benchmarks. The X-waiver elimination implementation gap is the most operationally specific shortfall against a legal-reform-that-did-not-produce-workforce-expansion.

The federal-rep leverage points concentrate here. MHBG and SABG appropriations are direct federal-action levers. Medicaid rate-setting is the primary lever for the BH workforce shortage (rate-driven compensation gaps relative to commercial plus Medicare reimbursement predict the shortage pattern documented in HPSA-MH designations). CCBHC expansion is structurally protected by OBBBA exemption from new cost-sharing — the protective provision for the D3-relevant CCBHC stream. HRSA NHSC plus workforce-diversity programs reach the cumulative-disadvantage geography problem. IMD exclusion modification is unchanged by OBBBA; the NACo-led H.R. 5462 plus H.R. 6727 reform efforts are the active federal-rep lever. SAMHSA capacity restoration (Pattern 1 reversal — treated in the Infrastructure sub-domain) is urgency-elevated. OBBBA implementation specifics — state-directed payment caps and provider tax phase-down FY28-34 — carry forward pressure on CBH revenue and DBHIDS sustainability.

The SUD-MH treatment integration challenge sits at the bifurcation seam. OMHSAS administers MH (within DHS); DDAP is a separate cabinet-level department for SUD; the architectural separation creates a state-level bifurcation that DBHIDS reconciles at the local level via the unique combination of SCA plus county MH authority. The reconciliation is structural but the operational dual-diagnosis treatment integration remains variable across the DBHIDS contract network; patients with co-occurring SMI plus SUD (approximately 7,000-10,000 dual-diagnosis adults in PA-3) fall through coordination gaps. The CCBHC nine-component model is designed to address this. The September 2024 MHPAEA Final Rule's non-enforcement statement (May 15, 2025) plus PA Act 30 of 2020's implementation status are the active policy levers on the integration question.

The cumulative-disadvantage geography operates here at SD3 with measurable specificity. The HPSA-MH designations across PA-3 cluster in North/Northwest Core, parts of West Philadelphia outside University City, and West Oak Lane / Stenton / Wister sub-tracts of Northwest Philadelphia. These geographic patterns correlate with the HOLC 1937 redlined-mapping pattern and with Black population concentration (>50% in many tracts). The provider-density geography is the legacy of documented policy decisions: CMHC Act 1963 implementation underbuilt in Black neighborhoods; redlining-era community-investment patterns; Medicaid reimbursement-rate-driven workforce sorting toward higher-resourced areas. Workforce cultural-competency gap compounds the geography: even where providers are present, cultural-mismatch reduces voluntary utilization by Black PA-3 residents. The community-services capacity gap is borne disproportionately by populations who are simultaneously most likely to need services AND least likely to access them voluntarily — community-services investment alone, without provider-diversity plus cultural-competency plus community-trust-rebuilding, does not resolve the chain.

Geography & representation

Data provenance. PA-3 demographic baseline (2021 ACS 1-Year Estimates) and the D2 cumulative racial-equity findings are documented in the verified D2 file. FQHC § 330 funding posture (extended through December 2026) is documented in the verified D2 file. HealthChoices BH single-MCO Philadelphia model and CBH coverage scale (approximately 420,000 Philadelphia Medicaid recipients per FY26 DBHIDS testimony, May 2025) are documented in DBHIDS reporting and verified per TC-10. CCBHC framework (P.L. 114-255 § 223), BSCA expansion (P.L. 117-159), SUPPORT Act IMD parity for SUD (P.L. 115-271 § 1012; 42 U.S.C. § 1396n(l)), X-waiver elimination (CAA 2023 P.L. 117-328 § 1262 of Division FF effective December 29, 2022), and the OBBBA IMD exclusion preservation (42 U.S.C. § 1396d(a)(B) unchanged) are documented in federal statute and the verified D2 file. NACo H.R. 5462 plus H.R. 6727 IMD reform legislative tracking is documented in NACo material. DBHIDS contract network composition (Horizon House, RHD, JEVS, PHMC; Gaudenzia, Self Help Movement, NorthEast Treatment Centers, Eagleville; PHMC, Esperanza, Drexel 11th Street, FIGHT, Spectrum) is documented in DBHIDS public reporting. The DBHIDS outpatient MH program count current, ACT team count plus waitlist size FY26, OTP geographic distribution plus capacity in PA-3, PROS site count plus utilization, crisis residential capacity, outpatient MH appointment wait time current, X-waiver-post-elimination buprenorphine prescribing growth specific to Philadelphia, 1115 SUD IMD waiver plus SUPPORT Act IMD parity for SMI current PA plus federal status, PA Act 30 of 2020 implementation, SUD treatment capacity by ASAM level current PA-3, dual-diagnosis program count plus utilization in DBHIDS network, and PROS utilization rate FY26 are flagged for institutional-source retrieval.

PA-3 statistical profile. Adults with any MI in PA-3 approximately 130,000-145,000 (NSDUH applied); adults with SMI approximately 35,000-42,000; adults with SUD approximately 80,000-100,000 per structural inference (alcohol plus illicit plus Rx); subset with opioid use disorder approximately 15,000-25,000. Co-occurring SMI plus SUD: approximately 20-25% of SMI population have co-occurring SUD = approximately 7,000-10,000 dual-diagnosis adults in PA-3. Service capacity baseline: CBH approximately 420,000 Philadelphia Medicaid recipients; DBHIDS network approximately 50-60 outpatient MH programs, 15-20 ACT teams, multiple OTPs, PROS sites; ACT team waitlist approximately 2,000-3,000 unserved eligible across providers; outpatient MH wait time 4-8 weeks adult and 3-6 months child / adolescent specialty; HPSA-MH designations across multiple PA-3 census tracts; OTP capacity concentrated regionally with PA-3 OTP density flagged; buprenorphine prescribing post-X-waiver elimination growth below expected.

Geographic variation.

• North/Northwest Philadelphia Core. Highest SD3 service-need and lowest SD3 service-access. HPSA-MH coverage extensive. Provider density lowest in PA-3. SUD service-utilization weighted toward Kensington-area providers (outside PA-3 strict boundary; PA-3 residents travel for services). Outpatient MH wait times longest in this sub-area.
• West Philadelphia Core. Bifurcated. University City anchor concentration (Penn BH, Drexel BH, CHOP) — nominal high density but commercial-priority access asymmetry. Adjacent neighborhoods (Mantua, Kingsessing, Cobbs Creek) closer to North Core pattern. PHMC plus Spectrum FQHC integrated BH presence partial mitigation.
• Northwest Philadelphia. Heterogeneous. Higher-income tracts adequate provider access; lower-income tracts (Germantown, Stenton, West Oak Lane, Wister) closer to North Core pattern. PHMC FQHC sites partial mitigation.
• South/Southwest Philadelphia. Better access pattern than North Core. PHMC plus Esperanza-adjacent plus Jefferson plus Penn Center City accessible. SUD treatment residential less concentrated; MAT outpatient through FQHCs available.

Boundary-adjacent: Kensington (PA-1/PA-2) is the SUD treatment epicenter with Prevention Point Philadelphia and SOR-funded sites; PA-3 residents access services here. NET Lehigh OTP (Northeast Philadelphia) serves a portion of PA-3 residents.

Pathway tracing. Three pathways trace how SD3 architecture differentially routes constituents based on insurance status and presenting condition.

Pathway A — Medicaid-enrolled PA-3 adult with SMI seeking outpatient MH. Call CBH Member Services → routed to in-network outpatient program → appointment 4-8 weeks out → initial appointment (medication management plus therapy referral) → ongoing care subject to phantom-provider problem, session-cap NQTL of 8-10 sessions vs. medical/surgical no-cap, rate-driven workforce turnover → ACT team referral if SMI plus high-utilization indicators with waitlist 6+ months → PROS access for psychiatric rehabilitation if appropriate. Breakdown points: Step 2 wait time pushes some constituents to crisis pathway by attrition; Step 4 phantom-provider plus cultural-mismatch.

Pathway B — Medicaid-enrolled PA-3 adult with OUD seeking MAT. First-level decision: MAT through OTP (methadone) vs. OBOT (buprenorphine in primary care plus BH) → OTP requires daily dosing with transportation plus work-schedule burden, PA-3 residents may travel to Kensington-area or NET Lehigh → OBOT: any DEA-registered prescriber post-X-waiver elimination but supply limited, FQHC integrated BH provides some access, private PCPs uncommon in Medicaid → co-occurring SMI handled through DBHIDS-CBH SCA-MH consolidation with variable operational integration. Breakdown points: OTP geographic plus daily-dosing burden; OBOT supply-side gap despite legal reform; dual-diagnosis coordination operational gaps.

Pathway C — Uninsured PA-3 adult with SMI or SUD. FQHC integrated BH sliding fee → DBHIDS direct-funded base services through county-base-service stream (chronically capacity-constrained) → crisis-only access via CRC plus ED plus EMTALA (no continuity guarantee). Breakdown points: FQHC plus base-service capacity at every step; episodic-care-without-continuity pattern; insurance-eligibility cycling produces churn.

Representation question. The federal framework formally provides PA-3 residents the Olmstead community-services mandate; Medicaid behavioral-health entitlement (MH plus SUD); EPSDT for children; CCBHC PPS; PROS Medicaid coverage; SAMHSA SABG SUD treatment; SUPPORT Act IMD parity for SUD; X-waiver elimination removing prior restriction on buprenorphine. Medicaid-enrolled residents receive structurally comprehensive coverage but face 4-8 week wait times, 2,000-3,000 ACT team waitlist, phantom-provider network adequacy, OTP geographic burden, and the OBOT supply-side gap. Uninsured residents receive crisis-only access without continuity. Multiple compounding causes account for the gap: federal funding inadequacy; Medicaid rate inadequacy driving workforce shortage; HPSA-MH designations confirming federally-recognized provider shortage; cumulative-disadvantage geography producing provider-density gap aligned with redlined-geography; X-waiver elimination not translating to workforce expansion at expected scale; ERISA preemption blocking state-level commercial-insurance reach for self-funded employees; OBBBA Medicaid cuts pressure forward. SD3 represents the central representation gap of D3 — the gap between Olmstead / EPSDT / SUPPORT Act mandates and operational community-services capacity. Federal-rep leverage points: MHBG plus SABG appropriations; Medicaid rate-setting; CCBHC expansion (protected by OBBBA exemption per TC-03); HRSA NHSC plus workforce diversity programs; IMD exclusion modification (NACo H.R. 5462 / H.R. 6727 pending; unchanged by OBBBA per TC-03); SAMHSA capacity restoration (urgency elevated per TC-06); OBBBA implementation specifics (state-directed payment caps plus provider tax phase-down FY28-34). SD3 is the federal-rep-leverage-richest sub-domain in D3.

Gap analysis

Gap 1 — ACT team waitlist as Olmstead-mandate operational shortfall (G3-SD3-01). Approximately 2,000-3,000 PA-3 residents with SMI eligible for ACT (Assertive Community Treatment) but unserved due to capacity constraints. ACT is the highest-intensity community-based service for SMI; the waitlist directly contradicts the Olmstead community-integration mandate. Federal-rep leverage at SAMHSA ACT expansion grants plus Medicaid rate-setting plus CCBHC PPS expansion (CCBHCs include ACT-equivalent services).

Gap 2 — Outpatient MH wait time as network-adequacy operational failure (G3-SD3-02). 4-8 week adult wait time plus 3-6 month child/adolescent specialty wait time exceeds reasonable network-adequacy benchmarks. CBH formally compliant; operationally degraded. Federal lever at September 2024 MHPAEA Final Rule network-adequacy NQTL (non-enforcement statement May 15, 2025; 2013 Rule plus CAA 2021 obligations remain operative); CMS oversight via 42 C.F.R. § 438.68; state OMHSAS enforcement.

Gap 3 — HPSA-MH provider shortage compound with cumulative-disadvantage geography (G3-SD3-03). HPSA-MH designations cluster in the same PA-3 sub-areas (North/Northwest Core; parts West; parts Northwest) that are documented as redlined-mapped plus Black-population-concentrated. The provider-density geography reproduces the cumulative-disadvantage pattern. Cross-cutting; resolves at SD7 synthesis. Federal-rep leverage at HRSA NHSC plus workforce-diversity programs.

Gap 4 — X-waiver elimination implementation gap (G3-SD3-04). CAA 2023 X-waiver elimination removed prior restriction on buprenorphine prescribing; the legal change has not produced proportionate workforce expansion. Supply-side shortage persists because rate inadequacy plus training plus cultural factors all separately constrain prescribing growth. Federal-rep leverage at Medicaid OBOT rate-setting; HRSA workforce programs; state-level licensure simplification.

Gap 5 — Bifurcated SUD-MH treatment integration challenge (G3-SD3-05). Co-occurring SMI plus SUD population (approximately 7,000-10,000 dual-diagnosis adults in PA-3) faces the OMHSAS-DDAP state-level bifurcation reconciled at local level by DBHIDS SCA-MH consolidation; operational dual-diagnosis treatment integration variable; patients fall through coordination gaps. State plus federal lever at integration; CCBHC nine-component model designed to address; September 2024 MHPAEA Rule plus PA Act 30 of 2020 implementation.

Gap 6 — Phantom-provider network-adequacy gap (G3-SD3-06). CBH network formally meets 200+ contracted-provider standard but operational capacity reduced by phantom-provider problem (providers in network not accepting new patients; providers at reduced capacity; nominal participation without active practice). Cross-reference SD1 G3-SD1-03. September 2024 MHPAEA Final Rule network-adequacy NQTL enforcement; CMS oversight; OMHSAS state enforcement.

Gap 7 — OTP geographic distribution plus daily-dosing burden (G3-SD3-07). Methadone OTPs concentrated in specific Philadelphia geographic locations (Kensington-adjacent for SUD-treatment historical reasons); daily dosing requirement burdens PA-3 residents with transportation plus work-schedule conflicts; PA-3 residents may travel to non-PA-3 OTPs. Federal-rep leverage at SAMHSA OTP regulation modernization (take-home dosing rule changes; mobile OTP authorization); state SCA-level OTP siting policy.

Gap 8 — SD3 as federal-rep-leverage-richest sub-domain in D3 (G3-XC-04 cross-cutting). SD3 has more federal-rep leverage points than other sub-domains: MHBG, SABG, Medicaid rate-setting, CCBHC expansion (CCBHC stream protected by OBBBA exemption per TC-03), HRSA NHSC, IMD exclusion modification (NACo H.R. 5462 / H.R. 6727 pending; unchanged by OBBBA per TC-03), SAMHSA capacity restoration (urgency elevated per TC-06), OBBBA implementation specifics (state-directed payment caps plus provider tax phase-down FY28-34). Synthesis-level finding.